CN116712483A - Synergistic liquid and preparation method and application method thereof - Google Patents
Synergistic liquid and preparation method and application method thereof Download PDFInfo
- Publication number
- CN116712483A CN116712483A CN202310734870.0A CN202310734870A CN116712483A CN 116712483 A CN116712483 A CN 116712483A CN 202310734870 A CN202310734870 A CN 202310734870A CN 116712483 A CN116712483 A CN 116712483A
- Authority
- CN
- China
- Prior art keywords
- parts
- micro powder
- powder
- synergistic liquid
- synergistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 56
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 105
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 28
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 27
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 27
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229940116229 borneol Drugs 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000008213 purified water Substances 0.000 claims abstract description 15
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 13
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 13
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 13
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 12
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 12
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 12
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 12
- 239000004863 Frankincense Substances 0.000 claims abstract description 12
- 241000601164 Clematis orientalis Species 0.000 claims abstract description 9
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 9
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 9
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000004745 nonwoven fabric Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 241000903946 Clematidis Species 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 241000112528 Ligusticum striatum Species 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 4
- 230000005669 field effect Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 12
- 210000004185 liver Anatomy 0.000 abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 238000006731 degradation reaction Methods 0.000 abstract description 2
- 238000010579 first pass effect Methods 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 229920000175 Pistacia lentiscus Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000036319 cervical spondylosis Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000005801 spondylosis Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, in particular to a synergistic liquid and a preparation method and a use method thereof, and discloses a synergistic liquid and a preparation method and a use method thereof, wherein the synergistic liquid comprises the following components: 3-5 parts of prepared Sichuan Wu Chao micro powder, 5-10 parts of frankincense micro powder, 5-10 parts of peach kernel micro powder, 5-10 parts of safflower micro powder, 5-10 parts of szechuan lovage rhizome micro powder, 5-10 parts of notopterygium root micro powder, 5-10 parts of divaricate saposhnikovia root micro powder, 5-10 parts of Chinese clematis micro powder, 0.05-0.1 part of borneol, 2-8 parts of azone and 30-50 parts of purified water. The synergistic liquid avoids the first pass effect of liver and the degradation of gastrointestinal tract through transdermal administration, improves the bioavailability of the medicine, improves the curative effect and reduces the toxic and side effects on human bodies. The patent follows the principle of dialectical prescription of traditional Chinese medicine in China, and also refers to the result of modern pharmacological research of traditional Chinese medicine, and the medicine can be introduced through meridian points, external treatment of internal diseases and targeting along the meridian, thereby achieving the efficacy of eliminating the disease of the medicine.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a synergistic liquid and a preparation method and a use method thereof.
Background
The society is developing, science is advancing, life span of human is also being prolonged, various chronic diseases accompanied with the increase of age are puzzled people's life, especially bone joint system's disease, from cervical vertebra, lumbar vertebra to four limbs joint, from twenty-three years old to seventy-eight years old, and coverage is widely affected by the pain the crowd the most. In recent decades, the number of cervical spondylosis, lumbar spondylosis, various bone joint diseases, rheumatism, rheumatoid diseases and other diseases is increased year by year due to the popularization of computer mobile phones, and the diseases are not cured for a long time and repeatedly attack, so that daily work and life are seriously affected. Some serious patients are solved through surgery, but the postoperative sequelae is more, the cost is high, the rehabilitation is slow, great pain and living burden are brought to the patients, most of the medicines are taken for a long time and are absorbed in intestines and stomach, metabolized in liver and kidney, and the liver is caused by taking for a long time. The kidney and intestines and stomach are greatly damaged, and the human body is injured. In addition, although some traditional Chinese medicine emplastrum overcomes the side effect of oral medicine and directly acts on the lesion part, the traditional Chinese medicine emplastrum has the advantages of numerous raw material medicines, complex preparation process, poor permeability, unstable effect, continuous emplastrum and increased local skin allergy rate.
Disclosure of Invention
The invention aims to provide a synergistic liquid, a preparation method and a use method thereof, which solve the problems of sequelae, high cost, slow recovery and great side effect of the traditional medicine after taking.
In order to achieve the above purpose, the invention is realized by the following technical scheme:
the invention provides a synergistic liquid, which comprises the following components: 3-5 parts of prepared Sichuan Wu Chao micro powder, 5-10 parts of frankincense micro powder, 5-10 parts of peach kernel micro powder, 5-10 parts of safflower micro powder, 5-10 parts of szechuan lovage rhizome micro powder, 5-10 parts of notopterygium root micro powder, 5-10 parts of divaricate saposhnikovia root micro powder, 5-10 parts of Chinese clematis micro powder, 0.05-0.1 part of borneol, 2-8 parts of azone and 30-50 parts of purified water.
Preferably, the synergistic liquid comprises the following components in percentage by weight: 3 parts of prepared Sichuan Wu Chao micro powder, 30 parts of purified water, 10 parts of frankincense micro powder, 10 parts of peach seed micro powder, 10 parts of safflower micro powder, 7 parts of szechuan lovage rhizome micro powder, 10 parts of notopterygium root micro powder, 10 parts of Chinese clematis root micro powder, 9.95 parts of divaricate saposhnikovia root micro powder and 0.05 part of borneol.
Preferably, the synergistic liquid comprises the following components in percentage by weight: 4 parts of prepared Sichuan Wu Chao micro powder, 40 parts of purified water, 8 parts of frankincense micro powder, 9.92 parts of peach seed micro powder, 8 parts of safflower micro powder, 6 parts of szechuan lovage rhizome micro powder, 8 parts of notopterygium root micro powder, 8 parts of Chinese clematis root micro powder, 8 parts of divaricate saposhnikovia root micro powder and 0.08 part of borneol.
Preferably, the synergistic liquid comprises the following components in percentage by weight: 4.5 parts of prepared Sichuan Wu Chao micro powder, 45 parts of purified water, 9 parts of frankincense micro powder, 7 parts of peach seed micro powder, 9 parts of safflower micro powder, 5.4 parts of szechuan lovage rhizome micro powder, 6 parts of notopterygium root micro powder, 7 parts of Chinese clematis micro powder, 7 parts of divaricate saposhnikovia root micro powder and 0.1 part of borneol.
The preparation method of the synergistic liquid is used for preparing the synergistic liquid, and the preparation method of the synergistic liquid comprises the following steps:
(1): wrapping 3-5 parts of prepared Sichuan Wu Chao micro powder with gauze, adding 30-50 parts of purified water ten times of prepared Sichuan Wu Chao micro powder, decocting to 100 ℃ by a decocting machine, decocting with slow fire for 60 minutes, filtering, and taking the filtrate for later use;
(2) Mixing 5-10 parts of frankincense superfine powder, 5-10 parts of peach kernel superfine powder, 5-10 parts of safflower superfine powder, 5-10 parts of ligusticum wallichii superfine powder, 5-10 parts of notopterygium root superfine powder, 5-10 parts of radix sileris superfine powder and 5-10 parts of radix clematidis superfine powder into powder, subpackaging the powder with a non-woven fabric bag, adding the non-woven fabric bag into a proper amount of purified water, soaking for 2-4 hours according to the ratio of (1:10) g/ml, dissolving active ingredients in the medicinal materials in a water solvent, and then mixing the solution with the liquid in the step (1) to obtain a suspension;
(3): pouring the suspension in the step (2) into an ultrasonic circulation extractor, extracting under the ultrasonic power of 350-450W, centrifuging the extracting solution at the rotating speed of 2500-3500r/min for 8-12min, and taking the upper clear liquid;
(4): dissolving 0.05 part of borneol into 95% ethanol, adding the supernatant clarified liquid after centrifugation in the step (3), and then adding 2-8% azone;
(5): adding azone into the filtrate obtained in the step (4), sterilizing by ultraviolet rays, and subpackaging in containers to obtain the synergistic liquid.
The application method of the synergistic liquid is used for the synergistic liquid, and the synergistic liquid can be used independently and is also suitable for the combined use of physical therapeutic apparatuses.
Preferably, the physical therapeutic apparatus is a field effect multifunctional therapeutic apparatus.
The medical science Wu Shiji of Qing dynasty proposes the principle of external treatment, i.e. internal treatment, through the application of external treatment. For external treatment, also for internal treatment, different kinds of herbs are indicated for the ears. The synergistic liquid is an external preparation, still follows the basic theory of traditional Chinese medicine and is prepared by combining the modern transdermal technology.
The pharmacological effects of the raw materials are as follows:
radix aconiti: [ Property ] Property: pungent, bitter and hot; [ Gui Jing ] is to enter heart, liver, kidney and spleen meridians, and its main actions are to dispel wind and remove dampness, warm meridians and stop pain. Can be used for treating arthralgia due to wind-cold-dampness, arthralgia, psychroalgia of heart and abdomen, cold hernia pain, and anesthesia and pain.
Mastic gum: [ nature and taste entering meridians ] nature Wen Wei: bitter, pungent, enter meridians: spleen channel, liver channel, heart channel, and the main indications of the "efficacy" are activating blood and relieving pain, detumescence and promoting tissue regeneration. Mainly treats; chest stuffiness and pain, epigastric pain, dysmenorrhea amenorrhea, postpartum stasis, abdominal mass, abdominal pain, rheumatalgia, spasm of tendons and vessels, traumatic injury, carbuncle, swelling and sore.
Peach kernel [ nature smell entering meridians ]: bitter and flat. It enters heart, liver, lung and large intestine meridians. [ Effect mainly ] the composition has the effects of activating blood and removing stasis, and is used for treating amenorrhea, dysmenorrhea, postpartum stasis, traumatic injury pain and constipation due to intestinal dryness.
Safflower: the nature and flavor and meridian tropism are warm in nature, pungent in flavor and meridian tropism, and the efficacy and indications are for activating blood and removing obstruction in collaterals, removing stasis and relieving pain, traumatic injury and joint pain.
Ligusticum wallichii: [ the nature and flavor of qi and meridian entered ] it is warm in nature and pungent in flavor, entering liver, gallbladder and pericardium meridian. [ FUNCTIONS ] can be used for treating wind-cold, wind-heat, rheumatism, blood stasis, and rheumatism paralysis.
Notopterygium root: [ the nature enters meridians ], is pungent and bitter, warm, enters bladder and kidney meridians. [ Effect mainly ] relieve exterior syndrome, dispel cold, dispel wind, remove dampness, and alleviate pain. Can be used for treating common cold due to wind-cold, headache, arthralgia due to wind-dampness, and soreness of shoulder and back.
Radix Clematidis: [ the nature enters meridians ] pungent, salty and warm. Enter bladder meridian. [ Effect mainly ] dispel wind-dampness, unblock the channels and collaterals. Can be used for treating rheumatalgia, numbness of limbs, spasm of tendons and vessels, and difficulty in flexing and extending.
Wind prevention: [ the nature enters meridians ]. It enters the urinary bladder, liver and spleen meridians. [ Effect mainly ] dispel wind and release exterior, dispel dampness and alleviate pain, stop spasm. Can be used for treating common cold, headache, rheumatalgia, rubella and pruritus.
Principle after synthesis:
the prepared common monkshood mother root in the above formula is pungent in taste, hot in nature, toxic (long-time decoction for detoxification), strong in strength, sharp in qi, capable of dispersing from inside to outside, capable of ascending and descending, dredging meridian, benefiting joint, warming meridian for dispelling cold, removing dampness and relieving pain, and capable of dredging cold due to congealing cold, and is a monarch drug. Semen Persicae has effects of removing blood stasis, moistening dryness, and Carthami flos has effects of promoting blood circulation, removing blood stasis, relieving pain, and rhizoma Ligustici Chuanxiong has effects of promoting blood circulation, removing blood stasis; is taken as ministerial drug. Mastic gum: promoting blood circulation, relieving pain, detumescence, promoting granulation, dispelling pathogenic wind, removing dampness, dispelling cold, and relieving pain; radix sileris has the effects of dispelling wind and relieving exterior syndrome, eliminating dampness and relieving pain; all the above are adjuvant drugs. Radix Clematidis is also used as a guiding drug for dispelling wind-dampness and dredging meridians. When the Chinese medicinal composition is used together, the main and collateral channels are dredged, the blood circulation is promoted, the blood stasis is removed, the qi circulation is carried out, and the pain is relieved, so that all symptoms can be cured.
Regarding transdermal effects of borneol and azone:
transdermal drug absorption promoting effect of borneol
Borneol can be absorbed by skin and promote the skin penetration process of other medicines. Borneol has different transdermal rates in different solvents, intercellular lipid permeation is an important path for transdermal permeation of borneol, and hydration enhancement of skin can also promote permeation of borneol. The effect of borneol on promoting transdermal absorption is mainly on the stratum corneum, probably due to the fact that borneol alters the arrangement of lipid molecules and increases its fluidity. In addition, borneol can also increase the depot effect of intact skin and the skin with the stratum corneum removed. It has also been suggested that borneol may be useful in promoting the transdermal action of drugs by dilating subcutaneous capillaries, thereby facilitating the entry of drugs into the blood circulation. By utilizing the skin research of in vitro rats, the borneol can obviously promote the transdermal absorption of the medicine at the concentration of 1%, 2% and 3%, wherein the concentration of 2% has the strongest effect, and the permeability coefficient is 6.1 times that of the borneol.
An anti-inflammatory effect; the main components in borneol, namely borneol and isoborneol, can inhibit the plantar swelling of rat caused by egg white, the principle of the borneol is possibly related to antagonism of PGE and inhibition of inflammatory mediator release, but the inhibition effect on auricle swelling of mice caused by croton oil is not completely the same, and the effect of borneol is not obvious.
Transdermal drug absorption promoting effect of azone
Laurocapram (AZONE) chemical name 1-dodecyl-hexahydro-2H-azepin-2-one CAS C18H35NO AZONE is a novel efficient transdermal absorption promoter appearing on the international market in the sixties, which opens up new fields of transdermal absorption and shows incomparable superiority in many aspects. The maximum characteristic of azone is that it has strong surface activity, can be inhaled into human body through skin, and its dosage is small (1-3%), and has no toxicity, smell and side effect
The invention has the beneficial effects that:
(1): the synergistic liquid avoids the first pass effect of liver and the degradation of gastrointestinal tract through transdermal administration, improves the bioavailability of the medicine, improves the curative effect and reduces the toxic and side effects on human bodies. The patent follows the principle of dialectical prescription of traditional Chinese medicine in China, and also refers to the result of modern pharmacological research of traditional Chinese medicine, and the medicine can be introduced through meridian points, external treatment of internal diseases and targeting along the meridian, thereby achieving the efficacy of reaching the disease.
(2): the synergistic liquid is a compound preparation which is formed by applying the principle of channel tropism of traditional Chinese medicines and the efficacy of the medicines which are mutually coordinated, and is directly applied to skin and acupuncture points, so that the medicinal herbs with thick smell are taken from the synergistic liquid, and are led to the medicine, lead to group medicine, open the junction and remove stagnation, and directly reach the disease. Can penetrate into skin to produce antiinflammatory and analgesic effects. Promoting blood circulation, removing blood stasis, dredging channels and collaterals, inducing resuscitation, dispelling pathogenic wind and cold, etc. The synergistic liquid acting on the body surface can stimulate nerve endings, promote local blood circulation by reflecting and expanding blood vessels, improve blood circulation of surrounding tissues and achieve the purposes of detumescence, anti-inflammation and analgesia. Meanwhile, the medicine can penetrate into subcutaneous tissue through skin at an affected part to generate the relative advantage of medicine concentration at local part, thereby exerting stronger pharmacological action.
(3): the synergistic liquid is a pure traditional Chinese medicine preparation, is developed by combining the mechanism of a modern external medical device, namely a field effect multifunctional therapeutic instrument, has the advantages of no injection and no drug taking, has little pain, no operation, short treatment course, quick response and no repeated attack, has obvious curative effects on cervical spondylosis, lumbar spondylosis, various bone joint diseases, rheumatism, rheumatoid diseases and other bone injury diseases, has the effective rate of more than 95 percent, improves the disease focus of bone repair, enhances the cell vitality by targeting drug guiding through the channels and collaterals and acupoints of a human body, fully exerts the drug effect from the outside to the inside, adjusts the disease resistance of the organism, has the synergistic effect among the drug effects of the Chinese herbal medicines in the formula, exerts the regulating effect of the herbaceous plants on the life functions, has scientific prescription, simple preparation method, easy processing, low manufacturing cost and wide applicable crowd, and is convenient for clinical application.
Detailed Description
The following describes the invention in further detail with reference to examples. The following examples are only for more clearly illustrating the technical aspects of the present invention, and are not intended to limit the scope of the present invention.
Example 1
The preparation method comprises the following specific steps:
(1): wrapping 3 parts of prepared Sichuan Wu Chao micro powder with gauze, adding 30 parts of purified water ten times of prepared Sichuan Wu Chao micro powder, decocting to 100 ℃ by a decocting machine, decocting with slow fire for 60 minutes, and filtering to obtain a liquid for later use;
(2) Mixing 10 parts of frankincense superfine powder, 10 parts of peach kernel superfine powder, 10 parts of safflower superfine powder, 7 parts of ligusticum wallichii superfine powder, 10 parts of notopterygium root superfine powder, 10 parts of radix clematidis superfine powder and 9.95 parts of radix sileris superfine powder into powder, subpackaging the powder with a non-woven fabric bag, adding the non-woven fabric bag into proper amount of purified water, soaking the non-woven fabric bag for 3 hours according to the ratio of (1:10) g/ml, so that the active ingredients in the medicinal materials are dissolved in a water solvent, and then mixing the water solution with the liquid in the step (1) to obtain a suspension;
(3): pouring the suspension in the step (2) into an ultrasonic circulation extractor, extracting under the condition that the ultrasonic power is 400W, centrifuging the extracting solution at the rotating speed of 3000r/min for 10min, and taking the upper clear liquid;
(4): dissolving 0.05 part of borneol into 95% ethanol, adding the supernatant clarified liquid after centrifugation in the step (3), and then adding 8% azone;
(5): adding azone into the filtrate obtained in the step (4), sterilizing by ultraviolet rays, and subpackaging in containers to obtain the synergistic liquid.
The synergistic liquid, the synergistic pad and the multifunctional therapeutic apparatus are used together, so that the synergistic liquid, the synergistic pad and the multifunctional therapeutic apparatus are not used alone, a researcher and a researcher independently treat 100 patients, the medicines are randomly divided into two groups, an experimental group and a control group, the experimental group uses products obtained by the penetrating liquid, the control group uses other traditional Chinese medicine emplastrum in the market, the course of disease is more than 6 months, the dosage of the synergistic liquid is that the synergistic liquid is sprayed on a special synergistic pad during treatment, 15ml of penetrating liquid is sprayed on each synergistic pad, one group of two synergistic pads is used, the field effect multifunctional therapeutic apparatus is used for medicine penetration, the dosage of the traditional Chinese medicine emplastrum is 20 g for each patch, the usage is once daily, 30 minutes each time, 7 days is a course of treatment, and the synergistic liquid is acted on corresponding meridian points of a diseased part of the patient during external application.
Curative effect condition judgment standard:
and (3) curing: the uncomfortable symptoms and the signs disappear, and the functional activities are recovered to be normal;
the method is effective: the uncomfortable symptoms and physical signs are reduced or partially disappeared, so that the life can be self-care;
invalidation: the discomfort symptoms and the physical signs are not improved.
The treatment effect is as follows:
100 patients were treated by the method, and after 4 weeks of continuous treatment, the treatment conditions of the patients were counted, as shown in the following table:
the foregoing is only a preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art, who is within the scope of the present invention, should make equivalent substitutions or modifications according to the technical scheme of the present invention and the inventive concept thereof, and should be covered by the scope of the present invention.
Claims (7)
1. The synergistic liquid is characterized by comprising the following components in percentage by weight: 3-5 parts of prepared Sichuan Wu Chao micro powder, 5-10 parts of frankincense micro powder, 5-10 parts of peach kernel micro powder, 5-10 parts of safflower micro powder, 5-10 parts of szechuan lovage rhizome micro powder, 5-10 parts of notopterygium root micro powder, 5-10 parts of divaricate saposhnikovia root micro powder, 5-10 parts of Chinese clematis micro powder, 0.05-0.1 part of borneol, 2-8 parts of azone and 30-50 parts of purified water.
2. The synergistic liquid as claimed in claim 1, wherein the synergistic liquid comprises the following components: 3 parts of prepared Sichuan Wu Chao micro powder, 30 parts of purified water, 10 parts of frankincense micro powder, 10 parts of peach seed micro powder, 10 parts of safflower micro powder, 7 parts of szechuan lovage rhizome micro powder, 10 parts of notopterygium root micro powder, 10 parts of Chinese clematis root micro powder, 9.95 parts of divaricate saposhnikovia root micro powder and 0.05 part of borneol.
3. The synergistic liquid as claimed in claim 1, wherein the synergistic liquid comprises the following components: 4 parts of prepared Sichuan Wu Chao micro powder, 40 parts of purified water, 8 parts of frankincense micro powder, 9.92 parts of peach seed micro powder, 8 parts of safflower micro powder, 6 parts of szechuan lovage rhizome micro powder, 8 parts of notopterygium root micro powder, 8 parts of Chinese clematis root micro powder, 8 parts of divaricate saposhnikovia root micro powder and 0.08 part of borneol.
4. The synergistic liquid as claimed in claim 1, wherein the synergistic liquid comprises the following components: 4.5 parts of prepared Sichuan Wu Chao micro powder, 45 parts of purified water, 9 parts of frankincense micro powder, 7 parts of peach seed micro powder, 9 parts of safflower micro powder, 5.4 parts of szechuan lovage rhizome micro powder, 6 parts of notopterygium root micro powder, 7 parts of Chinese clematis micro powder, 7 parts of divaricate saposhnikovia root micro powder and 0.1 part of borneol.
5. A method for preparing a synergistic liquid for preparing the synergistic liquid as claimed in any one of claims 1 to 4, characterized in that the method for preparing the synergistic liquid comprises the following steps:
(1): wrapping 3-5 parts of prepared Sichuan Wu Chao micro powder with gauze, adding 30-50 parts of purified water ten times of prepared Sichuan Wu Chao micro powder, decocting to 100 ℃ by a decocting machine, decocting with slow fire for 60 minutes, filtering, and taking the filtrate for later use;
(2) Mixing 5-10 parts of frankincense superfine powder, 5-10 parts of peach kernel superfine powder, 5-10 parts of safflower superfine powder, 5-10 parts of ligusticum wallichii superfine powder, 5-10 parts of notopterygium root superfine powder, 5-10 parts of radix sileris superfine powder and 5-10 parts of radix clematidis superfine powder into powder, subpackaging the powder with a non-woven fabric bag, adding the non-woven fabric bag into a proper amount of purified water, soaking for 2-4 hours according to the ratio of (1:10) g/ml, dissolving active ingredients in the medicinal materials in a water solvent, and then mixing the solution with the liquid in the step (1) to obtain a suspension;
(3): pouring the suspension in the step (2) into an ultrasonic circulation extractor, extracting under the ultrasonic power of 350-450W, centrifuging the extracting solution at the rotating speed of 2500-3500r/min for 8-12min, and taking the upper clear liquid;
(4): dissolving 0.05 part of borneol into 95% ethanol, adding the supernatant clarified liquid after centrifugation in the step (3), and then adding 2-8% azone;
(5): adding azone into the filtrate obtained in the step (4), sterilizing by ultraviolet rays, and subpackaging in containers to obtain the synergistic liquid.
6. A method of using the synergistic liquid of any one of claims 1 to 4, wherein the synergistic liquid is used alone and is also suitable for use in combination with a physical therapeutic apparatus.
7. The method of claim 6, wherein the physical therapeutic apparatus is a field effect multifunctional therapeutic apparatus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310734870.0A CN116712483A (en) | 2023-06-20 | 2023-06-20 | Synergistic liquid and preparation method and application method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310734870.0A CN116712483A (en) | 2023-06-20 | 2023-06-20 | Synergistic liquid and preparation method and application method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116712483A true CN116712483A (en) | 2023-09-08 |
Family
ID=87873095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310734870.0A Pending CN116712483A (en) | 2023-06-20 | 2023-06-20 | Synergistic liquid and preparation method and application method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116712483A (en) |
-
2023
- 2023-06-20 CN CN202310734870.0A patent/CN116712483A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103263551A (en) | Powder for external use for relieving swelling and dispersing blood stasis | |
| CN104274546A (en) | Externally-applied traditional Chinese medicine composition, externally-applied traditional Chinese medicine preparation as well as preparation method and application of externally-applied traditional Chinese medicine composition | |
| CN102526406B (en) | Traditional Chinese medicine plaster for treating cervical spondylotic radiculopathy and preparation method thereof | |
| CN1292777C (en) | External applied Chinese traditional medicine plaster for curing facial paralysis and process for preparing the same | |
| CN107412640B (en) | External ointment for assisting acupuncture and moxibustion physiotherapy | |
| CN116712483A (en) | Synergistic liquid and preparation method and application method thereof | |
| CN114306436A (en) | A Chinese medicinal composition cataplasma for treating osteoarticular pain and preparation method thereof | |
| CN1194718C (en) | Meridians-activating pain-alleviating plaster for treating pains of neck, shoulder, waist and leg | |
| CN102068647B (en) | Chinese medicinal composition for treating lumbocrural pains by ironing and warming | |
| CN1485071A (en) | Medicine for curing hydrocephalus, brain abscess and brain tumor and preparation process thereof | |
| CN111821413A (en) | Traditional Chinese medicine composition for treating diarrhea and hypodynamia as well as preparation and application thereof | |
| CN110478418A (en) | A kind of liniment for myogenic of easing pain | |
| CN104258285A (en) | Medicine for treating lumbar bone hyperplasia through internal and external application and preparation method thereof | |
| CN109793849A (en) | One kind dispel releasing ache and health care patch | |
| CN115040574B (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating thyroid nodule and preparation method thereof | |
| CN108904705A (en) | A kind of Chinese medicine composition for treating postmenopausal women gouty arthritis,chronic | |
| CN116173160B (en) | External swelling-diminishing pain-relieving formula and application thereof | |
| CN105560537A (en) | Medicine composition for treating osteoartritis and preparation method thereof | |
| CN101313944B (en) | Herbal pain penetrating fluid | |
| CN114767776A (en) | External medicinal liquor for treating lumbar disc herniation | |
| CN106266388B (en) | A topical medicated liquor for treating bone impediment, promoting blood circulation and relieving pain, and its preparation method | |
| CN114984170A (en) | Traditional Chinese medicine composition for treating lumbocrural pain and preparation method and application thereof | |
| CN104888147A (en) | Traditional Chinese medicine ointment for shoulder periarthritis and preparation method thereof | |
| CN115105580A (en) | A topical Chinese medicinal composition containing nervonic acid for relieving swelling and pain, and its preparation method | |
| CN110420302A (en) | It is a kind of for transdermal prescription of gastroenteritis and preparation method thereof and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |